Abstract
The recent surge in cancer drug approval has provided us in cardio-oncology with a new and unique era, which modern medicine has not experienced before: the diminishing availability of “conventional” evidence-based medicine. The drastic and quick changes in oncology has made it difficult, and at times even impossible, to establish a meaningful evidence-based cardio-oncology practice by simply following the oncologists' practice. For the modern cardio-oncologist, it seems that a more proactive approach and methodology is needed. We believe that only through such an approach (learn from the old, and apply to the new) the cardio-oncologist will obtain meaningful evidence to perform their every-day practice in this new era.
Original language | English (US) |
---|---|
Article number | 601893 |
Journal | Frontiers in Cardiovascular Medicine |
Volume | 7 |
DOIs | |
State | Published - Nov 25 2020 |
Keywords
- anthracycline
- cardio-oncology
- evidence-based medicine
- onco-cardiology
- trastuzumab
- type 1 and type 2 cardiotoxicity
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine